
MAY 0 9 2002



PTO/SB/01A (10-00).
Approved pryses through 10/31/2002. OMB 0651-0032. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	rention COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER			
As the below named inventor(s), I/we declare that: This declaration is directed to: The attached application, or				
:	No. 10/076,622, filed on February 13, nded on (if applicable);	<u>2002,</u>		
_	m/are the original and first inventor(s)	of the subject	matter which is claimed and for	
	l understand the contents of the above dment specifically referred to above;	-identified app	lication, including the claims, as	
known to me/us to be which became available	duty to disclose to the United States material to patentability as defined in between the filing date of the prior appartion-in-part application, if applicable;	37 CFR 1.56 plication and t	including material information	
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.				
FULL NAME OF INVEN	TOR(S)	·		
Inventor one: Raym	nond L. Houghton	Citizen of:	US	
Signature:	and he fought	Date:	3/29/02	
Inventor two: Paul I	R. Sleath	Citizen of:	US	
Signature: Lau	I Robbe	Date:	3/29/02	
Inventor three: David	H. Persing	Citizen of:	US	
Signature:	wh	Date:	4-5-02	
Inventor four:		Citizen of:		
Signature:		Date:		
☐ Additional inventors	are being named on additional form	(s) attached he	reto	

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231. Docket No. 210121.470C11 265544

MAY 0 9 2002

+

S MAIL NO. EV064838741US

PTO/SB/81 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required.

ELECTION AND POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

to require the total content of intermation arrices it and playe a value of the remiter manifest			
Application Numb r	10/076,622		
Filing Date	February 13, 2002		
First Named Inventor	Raymond L. Houghton		
Group Art Unit			
Examiner Name			
Attorney Docket Number	210121.470C11		

I hereby ap ☑ Practition OR ☐ Practition	ners at Se	ed IP Law Group PLLC ned below:		00500 PATENT TRADEMARK	OFFICE
Г			T		1
-		Name	Registrat	ion Number	
		or agent(s) to prosecute the application id nected therewith.	entified above, and to	transact all business	in the Patent and
	-	rrespondence address for the above-ident ed Customer Number.	ified application to:		
Firm <i>or</i>	al Name				
Address					
Address					
City		S	tate	ZIP	
Country		1		<u></u>	· · · · · · · · · · · · · · · · · · ·
Telephone	Telephone Fax				
I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). As assignee of record of the entire interest I/we hereby elect, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventor.					
		SIGNATURE of Applicant	or Assignee of Rec	ord	
Name	Name Kathleen Nora McKereghan				
Signature	(a,C)	Chample			
Date 2 May 2002 ()					
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.					
Total of		if more than one signature is required, s ns are submitted.	see below.		
unden Heur Ctet					

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



SIGNMENT OF UTILITY PATENT APPLICATION

MAY 0 9 2002 (2) WEMEREAS, we,

Name TRADE	Post Office Address	
Raymond L. Houghton	2636 242nd Place Southeast, Bothell, WA 98021	;
Paul R. Sleath	1623 Eighth Avenue West, Seattle, WA 98119	; and
David H. Persing	22401 Northeast 25th Way, Redmond, WA 98053	,

(hereinafter referred to as ASSIGNORS), having post office addresses as listed above next to our names, are the joint inventors of an invention entitled

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER

which is described and claimed in the specification and claims of continuation-in-part (C-I-P) Patent Application No. 10/076,622, as filed in the United States Patent and Trademark Office on February 13, 2002 ("this application") for which a patent is sought. This application derives benefit from the following application(s):

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number	Attorney Docket Number
10/007,805	12/07/01		210121.470C10
09/834,759	04/13/01		210121.470C9
09/620,405	07/20/00		210121.470C8
09/604,287	06/22/00		210121.470C7
09/590,751	06/08/00		210121.470C6
09/551,621	04/17/00		210121.470C5
09/433,826	11/03/99		210121.470C4
09/389,681	09/02/99		210121.470C3
09/339,338	06/23/99		210121.470C2
09/285,480	04/02/99		210121.470C1

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number	Attorney Docket Number	
. 09/222,575	12/28/98		210121.470	

WHEREAS, Corixa Corporation (hereinafter referred to as ASSIGNEE), a corporation of the State of Delaware having a place of business at 1124 Columbia Street, Suite 200, Seattle, Washington 98104, is desirous of acquiring the entire right, title and interest in and to said invention, this application, and in and to any Letters Patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNORS hereby sell, assign and transfer unto said ASSIGNEE, the entire right, title and interest in and to said invention, this application and any and all Letters Patent which may be granted therefor in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from this application and said parent application(s) to which said foreign applications are entitled by virtue of international convention, treaty or otherwise; said invention, this application and all Letters Patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, transfer and sale not been made.

ASSIGNORS hereby authorize and request the Director of the Patent and Trademark Office to issue said United States Patent to ASSIGNEE, of the entire right, title and interest in and to the same, for its sole use and benefit, and for the use and behalf of its legal representatives, to the full end of the term for which said Patent may be granted, as fully and entirely as the same would have been held by us had this assignment and sale not been made.

ASSIGNORS agree to execute all instruments and documents required for the making and prosecution of applications for United States and foreign Patent on said invention,

Patent therefor.
3/29/02 Rayout a Hought
Date Raymond L'Houghton
State of
County of
I certify that I know or have satisfactory evidence that Raymond L.Houghton is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument. Dated Dated Dated
Signature of Notary Public Notary Public
Printed Name DEIRDRE I. BRYAN
My appointment expires $9/1/02$
Date 3/29/02 Paul R. Sleath
State of having NGTON
County of KING) ss.
I certify that I know or have satisfactory evidence that Paul R. Sleath is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.
Dated
Signature of Notary Public Mendie & Coryan
Printed Name DEIRDRE I. BRYAN
My appointment expires9/1/02

for litigation regarding said Patent, or for the purpose of protecting title to said invention or

	4/5/02		Man John	
Date .	/		David H. Persing	
State of	WASHINGTON)		
Country of	KINC)	SS.	

I certify that I know or have satisfactory evidence that David H. Persing is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated	epril 5 2002	
Signature of Notary Public	Wendre I Bryan	_
Printed Name	DEIRDRE I. BRYAN	
My appointme	at expires 9/1 /0 Z	

265583



results of BLAST

BLASTP 2.2.6 [Apr-09-2003]

Reference:

Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

RID: 1061299431-06061-3105

Query=

(50 letters)

Database: All non-redundant GenBank CDS

translations+PDB+SwissProt+PIR+PRF

1,503,231 sequences; 484,217,701 total letters


4,17,2000

If you have any problems or questions with the results of this search please refer to the **BLAST FAQs**

Taxonomy reports

4,1999

Distribution of 4 Blast Hits on the Query Sequence



Sequences producing significant alignments:

Score E (bits) Value

gi	16506285 ref NP_443723.1 breast cancer antigen NY-BR-	1	94	7e-19	L
gi	13469731 gb AAK27326.1 breast cancer antigen NY-BR-1.	1	65	4e-10	
	21758774 dbj BAC05379.1 unnamed protein product [Homo	s	56	2e-07	
gi	15678010 ref NP 274455.1 DNA polymerase III, subunits	$g\dots$	31	6.1	

Alignments

Get selected sequences | Select all Deselect all

```
Score = 93.6 bits (231), Expect = 7e-19
 Identities = 50/50 (100%), Positives = 50/50 (100%)
           MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG 50
Ouerv: 1
           MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG
Sbjct: 340 MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG 389
____>gi|13469731|gb|AAK27326.1|
                                breast cancer antigen NY-BR-1.1 [Homo sapiens]
          Length = 1011
 Score = 64.7 bits (156), Expect = 4e-10
 Identities = 36/50 (72%), Positives = 40/50 (80%)
           MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG 50
           + P KETSEKF+W AK R RKI WE+KET VKT CVA VT NKT+VLEKG
Sbjct: 187 LRPTKETSEKFSWPAKERSRKITWEEKETSVKTECVAGVTPNKTEVLEKG 236
sqi|21758774|dbj|BAC05379.1| unnamed protein product [Homo sapiens]
          Length = 168
 Score = 55.8 bits (133), Expect = 2e-07
 Identities = 37/50 (74%), Positives = 39/50 (78%)
Query: 1 MSPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTSNKTKVLEKG 50
          M AKETSEKF W AK RPRKI WE+KET VKT CVA V NKT+VLEKG
Sbjct: 47 MRTAKETSEKFAWPAKERPRKITWEEKETSVKTECVAGVIPNKTEVLEKG 96
| >gi | 15678010 | ref | NP 274455.1 | DNA polymerase III, subunits gamma and tau, progra
           [Neisseria meningitidis MC58]
          Length = 704
 Score = 30.8 bits (68), Expect = 6.1
 Identities = 18/40 (45%), Positives = 25/40 (62%), Gaps = 1/40 (2%)
Query: 2
           SPAKETSEKFTWAAKGRPRKIAWEKKETPVKTGCVARVTS 41
           SP+ +T+EK T A K +PR A E +TPV+T
                                             A + S
Sbjct: 379 SPSAQTAEKETAAKKPQPRPEA-ETAQTPVQTASAAAMPS 417
     Get selected sequences
                             Select all
                                        Deselect all
  Database: All non-redundant GenBank CDS
  translations+PDB+SwissProt+PIR+PRF
    Posted date: Aug 18, 2003 4:29 AM
  Number of letters in database: 484,217,701
  Number of sequences in database: 1,503,231
Lambda
   0.308
            0.122
Gapped
Lambda
           K
   0.267
           0.0410
Matrix: BLOSUM62
Gap Penalties: Existence: 11, Extension: 1
Number of Hits to DB: 46,762,076
Number of Sequences: 1503231
Number of extensions: 1192855
Number of successful extensions: 1740
Number of sequences better than 10.0: 4
Number of HSP's better than 10.0 without gapping: 3
```

```
Number of HSP's successfully gapped in prelim test: 1
Number of HSP's that attempted gapping in prelim test: 1725
Number of HSP's gapped (non-prelim): 15
length of query: 50
length of database: 484,217,701
effective HSP length: 26
effective length of query: 24
effective length of database: 445,133,695
effective search space: 10683208680
effective search space used: 10683208680
T: 11
A: 40
X1: 16 ( 7.1 bits)
X2: 38 (14.6 bits)
X3: 64 (24.7 bits)
S1: 42 (21.7 bits)
S2: 66 (30.0 bits)
```





PTO/SB/96 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Approved to respond to a collection of information unless it displays a valid OMB control number.

STATE	MENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: Raym I	nd L. H ughton et al.
Application No./Patent No.: 10/076,	Filed/Issue Date: February 13, 2002
Entitled: COMPOSITIONS AND MET BREAST CANCER	HODS FOR THE THERAPY AND DIAGNOSIS OF
	, a <u>corporation</u>
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:	
1. X the assignee of the entire right,	title, and interest; or
2. an assignee of an undivided part	t interest
in the patent application/patent identifi	ed above by virtue of either:
The assignment was recorded i	r(s) of the patent application/patent identified above. In the United States Patent and Trademark Office at or which a copy thereof is attached.
B. A chain of title from the inventor current assignee as shown below	(s), of the patent application/patent identified above, to the w:
1. From:	To:
	in the United States Patent and Trademark Office at for which a copy thereof is attached
2. From:	To:
	n the United States Patent and Trademark Office at for which a copy thereof is attached
3. From:	To:
	n the United States Patent and Trademark Office at for which a copy thereof is attached.
Additional documents in the c	hain of title are listed on a supplemental sheet.
Copies of assignments or other do	cuments in the chain of title are attached.
[NOTE: A separate copy (i.e., the original a submitted to Assignment Division in accord of the USPTO. See MPEP 302.8]	ssignment document or a true copy of the original document) must be ance with 37 CFR Part 3, if the assignment is to be recorded in the records
The undersigned (whose title is suppli	ed below) is authorized to act on behalf of the assignee.
Date	Kathleen Nora McKereghan Typed or printed name
	Signature Senior Vice President, General Counsel and Secretary
•	Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.